Evidence map›Paper›PMID 36992342›Full record

ArticleViruses2023

Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents.

Naomi S Coombes, Kevin R Bewley, Yann Le Duff, Matthew Hurley, Lauren J Smith, Thomas M Weldon, Karen Osman, Steven Pullan, Neil Berry, Bassam Hallis and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Naomi S CoombesMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.ORCID 0000-0001-9631-6875
Kevin R BewleyMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.ORCID 0000-0002-9078-6734
Yann Le DuffDivision of Infectious Disease Diagnostics, National Institute for Biological Standards, Medicines and Healthcare Products Regulatory Agency, Potters Bar EN6 3QG, UK.
Matthew HurleyDivision of Infectious Disease Diagnostics, National Institute for Biological Standards, Medicines and Healthcare Products Regulatory Agency, Potters Bar EN6 3QG, UK.
Lauren J SmithMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
Thomas M WeldonMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.ORCID 0000-0002-2431-304X
Karen OsmanMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.ORCID 0000-0002-8095-3850
Steven PullanMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
Neil BerryDivision of Infectious Disease Diagnostics, National Institute for Biological Standards, Medicines and Healthcare Products Regulatory Agency, Potters Bar EN6 3QG, UK.
Bassam HallisMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
Sue CharltonMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
Yper HallMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
Simon G P FunnellMedical Interventions Group, UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the summer of 2020, it became clear that the genetic composition of SARS-CoV-2 was changing rapidly. This was highlighted by the rapid emergence of the D614G mutation at that time. In the autumn of 2020, the project entitled "Agility" was initiated with funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to assess new variants of SARS-CoV-2. The project was designed to reach out and intercept swabs containing live variant viruses in order to generate highly characterised master and working stocks, and to assess the biological consequences of the rapid genetic changes using both in vitro and in vivo approaches. Since November 2020, a total of 21 variants have been acquired and tested against either a panel of convalescent sera from early in the pandemic, and/or a panel of plasma from triple-vaccinated participants. A pattern of continuous evolution of SARS-CoV-2 has been revealed. Sequential characterisation of the most globally significant variants available to us, generated in real-time, indicated that the most recent Omicron variants appear to have evolved in a manner that avoids immunological recognition by convalescent plasma from the era of the ancestral virus when analysed in an authentic virus neutralisation assay.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 SerotherapyHumansMutationPandemicsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2coronavirusimmune escapeSARS-CoV-2SARS-CoV-2 neutralisation assaySARS-CoV-2 variant

Identifiers

PMID36992342
PMCPMC10056478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.